Robert W. Duggan

Robert W. Duggan, listed as chief executive, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Pulse Biosciences, Inc., Achaogen, Inc. and Summit Therapeutics Inc. Over a trading history stretching from 9 February 2017 to 4 June 2026, the count stands at 165 filings.

Both buying and selling appear: 125 purchases worth €770.1M, against 6 sales worth €1.9M. On balance, insiders were net buyers of €768.2M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 20 share grants and 12 option exercises. So far in 2026, the count stands at 2 purchases and no sales.

Half of the purchases are above €480k and half below. Of 124 purchases, 62 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The newest entry dates from 4 June 2026: an open-market purchase of €1.3M, in Summit Therapeutics Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.